在COVID-19的背景下,垂体-目标腺轴对RAAS的影响
Baofeng Wu1,2, Ru Li1,2, Qinhao Liu1,2
1Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, 030001, China.
International journal of medical sciences
|August 27, 2025
概括
这篇评论探讨了脑下垂体激素和轴如何影响氨酸-氨酸-氨系统 (RAAS),提供了关于血压和水平衡的见解,尤其与正在进行的SARS-CoV-2再感染有关.
科学领域:
- 内分泌学
- 心血管生理学
- 脏生理学
背景情况:
- pituitary 腺体对于通过荷尔蒙分泌来调节新陈代谢,生长和繁殖至关重要.
- 氨酸 - 氨酸 - 氨酸系统 (RAAS) 对血压和液体平衡至关重要.
- 了解RAAS的病理生理学已经导致了显著的临床进展.
研究的目的:
- 审查垂体目标腺轴对RAAS的影响.
- 检查垂体激素对水电解质平衡和血压的影响.
- 在持续的SARS-CoV-2再感染的背景下提供新的视角.
主要方法:
- 专注于垂体激素与RAAS之间的相互作用的文献综述.
- 分析研究的垂体-甲状腺,垂体-上腺,垂体-生长激素和垂体-腺轴.
- 综合目前关于由 pituitary 因素调节的 RAAS 的知识.
主要成果:
- 下垂体目标腺轴显著调节RAAS活动.
- 下垂体激素在水电解质平衡和血压控制中起着复杂的作用.
- 在了解病毒感染期间的生理反应方面,相互作用尤为重要.
结论:
- 下垂体及其轴是RAAS的关键调节器.
- 对这些相互作用的进一步研究可以加强控制血压和液体平衡的策略.
- 本综述强调了涉及激素和心血管失调的疾病的潜在治疗点.
相关概念视频
Hypothalamic-Pituitary Axis
61.6K
The response to stress—be it physical or psychological, acute or chronic—involves activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is part of the neuroendocrine system because it involves both neuronal and hormonal communication. Its function is to regulate homeostatic systems—metabolic, cardiovascular, and immune—providing the necessary means to respond to a stressor.
61.6K
Antihypertensive Drugs: Direct Renin Inhibitors
819
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
819
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
875
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
875
Hypertension II: Pathophysiology
77
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
77
Neural Regulation of Blood Pressure
3.4K
The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
3.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505


